Biocon

In October 2022, Biocon Foundation, the CSR arm of the Bengaluru-headquartered Biocon Limited, was awarded the ‘Mahatma Award 2022 For Excellence in Social Good’.

In May 2022, Biocon Biologics and Viatris Inc launched a biosimilar product Abevmy (bBevacizumab) in Canada for use in the treatment of cancer.

In February 2022, Biocon got USFDA approval for its Posaconazole Delayed-Release tablets.

Biocon Biologics received RS. 555 crore (US$ 75 million) capital from ADQ, an Abu Dhabi based primary equity investment

To expand its generic formulations portfolio, Biocon launched Everolimus tablets in the US.

Biocon Biologics Limited (BBL) and Serum Institute Life Sciences Private Limited (SILS) announced a strategic alliance to develop antibodies for infectious diseases like dengue, HIV, and others.

Biocon Biologics received US$ 150 million capital injection from Goldman Sachs Semglee (insulin glargine injection) launched in the US

Tata Capital acquired minority stake in Biocon Biologics

True North makes a primary equity investment in Biocon Biologics

Bicara Therapeutics incorporated to advance novel immuno-oncology assets Ogivri, biosimilar Trastuzumab commercialised in the United States

Biosimilars business consolidated under independent entity Biocon Biologics Fulphila and Ogivri, jointly developed by Biocon and Mylan, was granted marketing authorisation by the European Commission

Biocon, Sandoz entered global partnership for the next-generation biosimilars

Biocon and Mylan’s biosimilar Insulin Glargine, Semglee, received European approval for commercialisation

Fulphila, jointly developed by Biocon and Mylan, approved and launched in the United States.

Biocon launched its biosimilar Bevacizumab in India

Biocon’s first overseas facility in Malaysia started operations

Biocon and Mylan becomes received US Food and Drug Administration (FDA) approval for biosimilar, Trastuzumab

Japan's health regulator approved the sale of its biosimilar, Insulin Glargine, in partnership with FUJIFILM Toyama Chemical

Biocon’s new insulin devices facility inaugurated in Bangalore

Biocon’s research services subsidiary, Syngene, debuted on the Indian stock market

Biocon and Pfizer entered into a strategic global agreement

Syngene inaugurated a fully dedicated research and development facility for Bristol-Myers Squibb at Biocon Park

Biocon launched Insulin Glargine under the brand name Basalog

Biocon, Mylan entered into strategic global partnership to develop biosimilars

Biocon acquired stake in AxiCorp GmbH, a German pharmaceutical company

Biocon divested its legacy enzymes business to Novozymes for US$115million to increase focus on developing, manufacturing biopharmaceuticals

India's largest multiproduct Biologics facility was inaugurated Biocon Park, India’s first private Biotechnology SEZ, was inaugurated

Biocon IPO was launched

Pichia-based rh-Insulin was developed and commercialised in India

Biocon Biopharmaceuticals was established as a JV with CIMAB, Cuba

Biocon Biopharmaceuticals was established as a JV with CIMAB, Cuba

Biocon become an independent entity

Unilever acquired 50% stake in Biochemizyme and created Biocon Quest India Ltd (BQIL), with Biocon and Unilever holding 50% stake each in the entity

Biocon established Syngene International Pvt. Ltd

Unilever acquired Biocon’s Irish Parent

Biocon established Syngene International Pvt. Ltd